| Autor: |
Atiq, Saad O, Gokhale, Tanmay, Atiq, Zainab, Holmes, Racquel, Sparks, Matthew A |
| Zdroj: |
Journal of Onco-Nephrology; February 2021, Vol. 5 Issue: 1 p23-26, 4p |
| Abstrakt: |
Immunotherapy has become a mainstay therapeutic in a variety of malignancies. Checkpoint inhibitors are used to enhance the endogenous immune response to target malignancy. The primary targets of checkpoint inhibitors include programed cell death receptor 1 (PD-1), programed cell death ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Despite clinical benefits, immune checkpoint inhibitors are associated with side effects termed immune-related adverse events (irAEs). We report a case of the PD-1 inhibitor (pembrolizumab) causing severe distal renal tubular acidosis (RTA). The patient presented with altered mental status and was found to have a severe non-anion gap metabolic acidosis after other potential etiologies were ruled out. We review the etiology of immune checkpoint inhibitor-induced RTA and review the case reports that have been described in the literature. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
